Common problems in ID

Review in internal medicine for R2

Pakpoom Phoompoung

Faculty of Medicine Siriraj Hospital

Outline

- **Organ specific infections**
- Selected specific pathogens
- HIV infection

Acute pharyngotonsilitis

- Most common: virus (rhinovirus & coronavirus)
- Only 5-10% caused by bacteria e.g. *Streptococcus pyogenes* (children & young adult)

Favor viral infections	Favor bacterial infections
▪ Coryza ▪ Cough ▪ Conjunctivitis ▪ Diarrhea ▪ Hoarseness	▪ Sudden onset of fever & sore throat ▪ Absence of cough ▪ Anterior cervical LN enlargement ▪ Exudative tonsil
Rx: Supportive treatment	Rx: Penicillin V 250 mg po qid or 500 mg po bid **x 10 D** Amoxicillin 1 g po OD or 500 mg po bid **x 10 D**

Acute exudative tonsilitis

≠ Streptococcus pyogenes

Organisms	Findings	Lymph node	Other findings	Treatment
S. pyogenes	Exudative tonsils & Forchheimer spot	Tender anterior cervical	Scarlatiniform rash	Amoxicillin
C. diphtheriae	Gray pseudomembrane beyond tonsils	Tender anterior cervical & submandibular	Bull neck	Macrolide DAT (Resp.)
EBV	Exudative tonsils & Forchheimer spot	Tender bilateral posterior cervical	Splenomegaly Rash esp. after ATB	Supportive Rx
Adenovirus	Exudative tonsils	Non-tender cervical & preauricular	Follicular conjunctivitis	Supportive Rx

Community acquired pneumonia

Bacteria	*S. pneumoniae, H. influenzae, M. catarrhalis* *K. pneumoniae* (alcoholic), *S. aureus* (post-influenza) *P. aeruginosa* (chronic lung disease) *B. pseudomallei* (DM, soil exposure, endemic area)
Atypical pathogens	*M. pneumoniae, C. pneumoniae* *L. pneumophila* (elderly, chronic lung disease, chronic smoker)
Virus	Influenza, Parainfluenza, Human metapneumovirus, RSV SARs-CoV2

Treatment for IPD patients: (ceftriaxone + macrolide) or fluoroquinolone

Complication

- Parapneumonic effusion

  (consider ICD if complicated; pH <7.2, LDH >900-1000, glucose <60 & empyema thoracis)

Pneumonia in IC host

Diseases	Susceptible host	Chest imaging	Investigation	Treatment
Nocardiosis	▪ AIDS (CD4 <100) ▪ Steroid use ▪ SOT	▪ Consolidation +/- cavitary lesion 	▪ mAFB +ve branching filament 	Bactrim +/- imipenem
Rhodococcosis			▪ mAFB +ve coccobacilli 	Levoflox + rifampicin + azithro
PCP		▪ Bilateral infiltration & GGO	▪ GMS/Giemsa ▪ IFA for PCP & PCR	Bactrim Steroid
Aspergillosis	▪ Neutropenia ▪ SOT & HSCT	▪ Halo sign ▪ Air crescent sign	▪ KOH (dichotomous branching septate hyphae) ▪ C/S & GM & histopatho	Voriconazole

Ventilator associated pneumonia

Essential practices for prevention (SHEA 2022)

- Avoid intubation and prevent reintubation by using HFNC or NIPPV as appropriate
- Minimize sedation and avoid benzodiazepines
- Maintain and improve physical conditioning
- Elevate the head of the bed to 30-45 degree
- **Provide oral care with toothbrushing without chlorhexidine**
- Provide early enteral versus parenteral nutrition
- Change the ventilator circuit only if visibly soiled or malfunctioning

No clear benefit

- Probiotics
- Frequent cuff-P monitoring
- Kinetic beds or prone
- Chlorhexidine oral care & bathing
- Stress-ulcer prophylaxis
- Monitor residual gastric volume

Infective endocarditis

Diagnosis

- Positive hemoculture
  - Typical organism: 2 separate bottles

    S. aureus, *S. lugdunensis*, all streptococci except GAS & S. pneumoniae, *Gamella* spp. *Granulicatella* spp., *Abiotrophia* spp., HACEK
  - Rare organism: 3 separate bottles
  - *C. burnettii*, *Bartonella* spp., *T. whipplei* PCR or antibody
- Typical imaging

Empirical treatment

- Native valve or late PVE: Ampicillin + cloxacillin + gentamicin
- Early PVE: vancomycin + rifampicin + gentamicin

Infective endocarditis

Specific treatment

Organisms	Treatment
Staphylococcus aureus	▪ **Native valve:** cloxacillin 12 g/day x 4-6 wk ▪ **Prosthetic valve:** cloxacillin 12 g/day x 6 wk + rifampicin 900-1200 mg/day x 6 wk + gentamicin 3 mg/kg/day x 2 wk
Viridans streptococci	▪ **MIC ≤0.125:** PGS 12-18 mu/day or ceftriaxone 2 g/day x 4 wk (may add gentamicin for shorter duration: 2 wk) ▪ **MIC 0.125-2:** PGS 24 mu/day or ceftriaxone 2 g/day x 4 wk must add gentamicin 3 mg/kg/day x 2 wk)
Enterococcus spp.	▪ Ampicillin 12 g/day x 4-6 weeks (must add gentamicin 2-6 weeks) ▪ **Alternative:** ampicillin + ceftriaxone 4 g/day (*E. faecalis* only)

Infective endocarditis

Emergent valve surgery

- Severe regurgitation/obstruction causing refractory pulmonary edema or cardiogenic shock (IB)

Urgent valve surgery

- Severe regurgitation/obstruction causing HF or echo sign of hemodynamic intolerance (IB)
- Uncontrolled infection
  - Locally uncontrolled infection (IB), MDR pathogens or fungi (IC), persisting positive H/C (IIA)
    PVE from *Staphylococcus aureus* or non-HACEK GNR (IIA)
- Prevention of embolism
  - >10 mm with one embolic event despite appropriate ATB (IB)
  - >10 mm with severe stenosis/regurgitation and low OR risk (IIA)
  - >15 mm (IIB), >30 mm (IIA)

Infective endocarditis

Dental procedures: manipulation with gingiva, periapical region, perforating the oral mucosa (not including Rx of superficial caries, dental x-ray, following the shedding of deciduous teeth)

Indication

- Prosthetic valve or prosthetic material used for valve repair
- Previous IE
- Unrepaired CHD or repaired CHD with residual defects
- Ventricular assist devices

Antibiotic prophylaxis

- Amoxicillin 2 g po 1 h before the procedure
- Penicillin allergy: cephalexin 2 g po
  or azithromycin/clarithromycin 500 mg po
  or doxycycline 100 mg po

Acute rheumatic fever

Revised Jones criteria
(Thai: mod-high risk)
2 Major
1 Major + 2 Minor

Major criteria
- Carditis
- Arthritis & polyarthralgia
- Sydenham's chorea
- Subcutaneous nodules
- Erythema marginatum

Minor criteria
- Fever (T ≥ 38 ^{o}C)
- Monoarthralgia
- Elevated ESR/CRP
- Prolonged PR interval

Evidence of prior GAS infection
- Throat swab C/S
- Streptococcal Ab (ASO/anti-DNaseB)

Treatment

1. **Streptococcal eradication**
   - Benzathine penicillin G 1.2 mu IM single dose
   - Penicillin V 500 mg po bid/tid for 10 D
   - Amoxicillin 1 g po OD x 10 D

2. **Streptococcal prophylaxis**
   - Benzathine penicillin G 1.2 mu IM q 3-4 wk
   - No carditis: 5 Y AND at least 21 YO
   - Carditis: 10 Y AND at least 21 YO
   - Carditis with residual disease: 10 Y AND at least 40 YO

3. **Anti-inflammatory therapy**
   - Aspirin
   - Prednisolone

Catheter-related BSI

CC: Fever with chills, may have hypotension

Dx: Positive peripheral vein H/C and no other apparent source for BSI **AND**

- Positive tip C/S of the same organism or
- Quantitative H/C ratio > 3:1 or differential time to positivity ≥2 h

Common organisms: *S. aureus*, CoNS, enteric GNRs, *Candida*

(↑ incidence of *P. aeruginosa* in long term catheter)

Treatment

- Antibiotic (longer duration if catheter in place)
- Catheter removal should be considered in high-risk patients

(severe sepsis, complicated infection, tunnel or port infection, exit site in short term CVC, high virulent pathogens: *S. aureus, P. aeruginosa, Candida* & NTM)

Catheter-related BSI

Type and organisms	Type	Catheter	ATB
Complicated	Short/long	Remove	ATB 4-6 weeks (6-8 weeks if osteomyelitis)
Tunnel infection/port abscess	Long	Remove	ATB 7-10 days
Uncomplicated			
CNS	Short	Remove	ATB 5-7 days
		Retained	ATB + ATB lock 10-14 days
	Long	Retained	ATB + ATB lock 10-14 days
S. aureus	Short/Long	Remove	ATB 14 days (short) or 4-6 weeks (long)
Enterococcus	Short	Remove	ATB 7-14 days
	Long	Retained	ATB + ATB lock 7-14 days
Gram negative bacilli	Short/long	Remove	ATB 7-14 days
Candida	Short/long	Remove	Antifungal 14 days

Catheter-related BSI

Essential practice for prevention (SHEA 2022)

- Bathe ICU patients over 2 months with **chlorhexidine**
- Subclavian site is preferred in ICU setting
- Use ultrasound guidance for catheter insertion
- Use **alcoholic chlorhexidine** antiseptic for skin preparation
- Disinfect hubs, connectors and injection ports before accessing the catheter
- Use **chlorhexidine-containing dressings** for CVCs in patients over 2 months
- Change transparent dressings every **7 days**
- Change gauze every **2 days** and change earlier if soiled, loose or damp
- Replace sets not used for blood products or lipids at intervals up to **7 days**

Acute bacterial meningitis

Clinical presentation

- Fever, headache, nausea and vomiting, alteration of consciousness
- Stiff neck (30%)

Investigation

- CSF pleocytosis with N predominate (Listeria – L), elevate protein, low sugar (CSF/serum < 0.4)

Common pathogens & empirical treatment

Conditions	Common organisms	Empirical antibiotics
<50 Y	*N. meningitidis, S. pneumoniae, S. suis* (pig)	Ceftriaxone 2 g IV q 12 h
>50 Y	Above + *L. monocytogenes, S. agalactiae*	Ceftriaxone 2 g IV q 12 h + ampicillin 2 g IV q 4 h
Pregnancy Alcoholism Steroid use	Above + *L. monocytogenes,* GNR	

Chronic meningitis

	TB meningitis	Cryptococcal meningitis
Susceptible hosts	▪ Immmunocompetent host ▪ HIV	▪ HIV (CD4 <100) ▪ SOT ▪ Anti-GM CSF autoAb
Manifestation	▪ Fever & stiff neck ▪ CN involvement (CN VI, III)	▪ Stiff neck may be absent esp. HIV
Brain imaging	▪ Hydrocephalus ▪ **Basal cistern meningeal enhance**	▪ **Gelatinous pseudocyst at BG**
CSF finding	▪ Pleocytosis with L predominate (N if early) ▪ **Very high protein** & low sugar ▪ C/S & PCR for TB	▪ Pleocytosis with L predominate (Low cell in HIV) ▪ High protein & low sugar ▪ India ink (Sn 60-80%) ▪ Cryptoccoccal Ag & C/S (Sn > 95%)
Treatment	▪ Anti-TB 9-12 M + steroid	▪ AMB + 5-FC → fluconazole

Acute viral encephalitis

Virus	Unique clinical characteristics	Imaging
HSV-1	**Immunocompetent host** Fever, behavioral change, seizure	Asymmetrical involvement of medial temporal lobe, inferior frontal lobe, insular cortex
HHV-6	**HSCT recipients esp. cord blood** Short term memory loss	Medial temporal lobe, hippocampus, thalamus
VZV	**Elderly, immunocompromised host** CN neuropathy, focal deficits, rash (60%)	Encephalitis: cerebellum, brainstem, temporal Vasculopathy: gray-white matter
CMV	**AIDS & SOT recipients** May have retinitis & radiculomyelitis	Subependymal and periventricular area
JE	**Living in endemic area** Seizure, extrapyramidal symptoms	Brainstem, thalamus, basal ganglia
Enterovirus	**Young adults** May have flaccid paralysis, HFMD	Non-specific EV71: posterior medulla, pons, cerebellum

- CSF (pleocytosis with L but N if early or CMV radiculo, normal or slightly ↓ sugar, normal or slightly ↑ protein)
- CSF PCR (low Sn if early HSV, VZV vasculopathy, JE, Enterovirus)

Acute diarrhea

Food poisoning

- Vomiting predominate: *S. aureus* (left over food), *B. cereus* (fried rice)
- Watery diarrhea: *B. cereus* (meat, vegetable), *C. perfringens* (canned foot, meat, poultry)

Acute gastroenteritis

- Watery diarrhea: norovirus (↑vomiting), rotavirus, ETEC, *V. cholerae* (voluminous)
- Mucous bloody diarrhea: EHEC, nontyphoidal *Salmonella*, *Shigella*, *V. parahaemolyticus*
  C. jejuni, C. difficile

Empirical treatment

- Mucous bloody diarrhea or severe watery diarrhea (e.g. high-grade fever)
- Ciprofloxacin or levofloxacin or azithromycin x 3 D

Peritonitis

	Spontaneous bacterial peritonitis	Secondary peritonitis	PD-associated peritonitis
Definition	▪ No break integrity of GI tract ▪ PMN > 250	▪ Conjunction with inflammation of GI tract	▪ On PD ▪ WBC >100 with PMN >50% (dwell for at least 2 h)
Pathogens	Monomicrobial ▪ *Enterobacterales* ▪ Streptococci	Polymicrobial ▪ Aerobic GPC & GNB ▪ Anaerobes	Monomicrobial > polymicrobial ▪ GPC & GNB ▪ Fungi
Treatment	▪ Ceftriaxone 7 D	▪ Source control ▪ Ceftriaxone + metronidazole 4-7 D after adequate source control	▪ IP cefazolin/vancomycin + ceftazidime (dwell for at least 6 h) x 2-3 wk ▪ IV ATB if sepsis ▪ Catheter removal if refractory/relapse or fungi

Tuberculous peritonitis

- WBC 150-4000 with L predominate (N in CAPD), protein >3 g/dL, low SAAG (high SAAG in cirrhosis), AFB/PCR & C/S: low Sn, ADA > 39 U/L (Sn 93% in non-cirrhosis)

Urinary tract infection

Diseases	Acute cystitis	Acute pyelonephritis
Clinical manifestations	Dysuria, urinary frequency, urgency, occasional hematuria or suprapubic pain	Fever +/- chills Flank pain & CVA tenderness
Investigation	▪ Pyuria (≥ 10 WBC/HPF centrifuged, ≥ 5 uncentrifuged urine) ▪ Significant bacteriuria (≥ 10^3 cystitis, ≥ 10^4 pyelonephritis) ▪ C/S is not necessary for 1st episode of cystitis	
Treatment	▪ PO nitrofurantoin > fosfomycin ▪ PO FQ should not be used (high collateral damage & lower suscep)	▪ IV ceftriaxone ▪ IV/PO fluoroquinolones (step down therapy →7 D)

Asymptomatic bacteriuria

- Significant bacteriuria (≥ 10^5) in asymptomatic patients
- Should be treated only in pregnant woman or patient undergoing uroSx with mucosal bleed

Catheter-associated UTI

Essential practice for prevention (SHEA 2022)

- Insert catheters only when necessary
- Use a catheter with the smallest feasible diameter
- Maintain a sterile, continuously closed drainage system
- Urine culture stewardship (do not sent if odorous or cloudy urine without S/S)

Should not be considered as routine

- Antimicrobial or antiseptic-impregnated catheters
- Screening for asymptomatic bacteriuria
- Catheter irrigation
- Systemic ATB prophylaxis
- Routine catheter change (only consider change for urine collection if >7 D)
- Antiseptic solution for meatal and perineal cleaning



Acute urethritis

Etiology

- Gonococcal urethritis: *N. gonorrhoeae*
- Nongonococcal urethritis
  - ✓ *C. trachomatis, M. genitalium*
  - ✓ *T. vaginalis,* HSV



Treatment

- Ceftriaxone 500 mg-1g IM single dose
- Azithromycin 1 g po single dose or doxycycline 100 mg po bid x 7 D



Common genital ulcer disease

	Herpes genitalis	Primary syphilis	Chancroid
Organisms	Herpes simplex virus	*Treponema pallidum*	*Hemophilus ducreyi*
Morphology	**Painful multiple** vesicles or shallow ulcerative lesions 	**Painless single** round ulcer with clean margin 	**Painful single** ulcer with undermined edge & exudates 
LN (if present)	Tender & bilateral	**Painless & bilateral**	Tender & expansive
Investigation	▪ Tzanck smear (low Sn) ▪ HSV antigen & PCR	▪ Darkfield microscopy ▪ VDRL/TPHA (false –ve)	▪ G/S: GNCB in long parallel strand (school of fish) ▪ Culture & PCR
Treatment	Acyclovir po/IV	Benzathine penicillin G 2.4 mU IM single dose	Azithromycin 1 g po single dose



Less common genital ulcer disease

	Granuloma inguinale (Donovanosis)	Lymphogranuloma venereum (LGV)
Organisms	*Klebsiella granulomatis*	*Chlamydia trachomatis* (L1-3)
Morphology	Painless firm subcutaneous nodule → progressive hypervascular ulcer (beefy red) and contact bleeding 	Painless transient small round ulcer (herpes-liked) with clean margins  
LN	No	**Extensive painful LN** (Groove sign)
Investigation	Wright stain (Donovan bodies)	PCR
Treatment	Azithromycin 1 g po OW or 500 mg po OD x 3 wk	Doxycycline 100 mg po bid x 3 wk

Skin & soft tissue infection

	Cellulitis	Necrotizing fasciitis
Clinical finding	Ill-defined erythematous, tender & swelling	▪ Severe disproportionate pain ▪ Hard & wooden feel ▪ Edema or tenderness extending beyond the erythema ▪ Crepitus or gas in soft tissue ▪ Bullous lesions ▪ Skin necrosis or ecchymoses
Pathogen	*S. pyogenes* & other streptococci *S. aureus*	▪ Polymicrobial infection ▪ *S. pyogenes, Clostridium* spp. ▪ *Aeromonas* spp., *Vibrio* spp.
Treatment	Cloxacillin or cefazolin or cephalexin Add clinda only for TSS	▪ Ceftriaxone + clindamycin ▪ PGS + clindamycin for GAS or Clostridia ▪ Adequate debridement

Skin & soft tissue infection

Risk factors	Pathogens
Cirrhosis	*Vibrio, Aeromonas*
Neutropenia	*Pseudomonas aeruginosa*
IVDU	*Pseudomonas aeruginosa, Staphylococcus aureus*
Dog bite	*Pasteurella multocida, Capnocytophaga canimorsus*
Cat bite	*Pasteurella multocida, Sporothrix* spp.
Human bite	*Eikenella corrodens*
Reptile bite	*Salmonella* spp.
Seawater	*Vibrio vulnificus, Mycobacterium marinum* (fish tank granuloma)

Augmentin

Septic arthritis

	Non-gonococcal	Gonococcal
Pathogens	▪ *S. aureus*, streptococci	▪ *N. gonorrhoeae*
Distribution	▪ Monoarthritis ▪ Oligo/polyarthritis in GBS or *S. aureus* in RA patients	▪ Migratory oligo/polyarthritis ▪ Tenosynovitis and skin lesions
Common location	▪ Knee/hip/ankle	▪ Knee/wrist/hand/ankle/foot
Investigation	▪ Blood C/S (Sn 50-70%) ▪ Joint fluid C/S	▪ Blood C/S (Sn low <50%) ▪ Joint fluid C/S (Sn very low < 10%) ▪ Urethral swab C/S (Sn 90%) Endocervical C/S (Sn 50-70%) in female
Treatment	▪ Ceftriaxone then deescalate ▪ Surgical drainage for medical failure or deep joint	▪ Ceftriaxone 1 g IV/IM OD x 7 D + azithro/doxycycline

Outline

- Organ specific infections
- **Selected specific pathogens**
- HIV infection

Streptococcus spp.

Species	Susceptible hosts	Common clinical syndromes
Streptococcus pyogenes (GAS)	▪ Normal host	• Acute pharyngotonsilitis • Skin and soft tissue infection • Toxic shock syndrome • ARF and post-streptococcal GN
Streptococcus agalactiae (GBS)	▪ Pregnancy ▪ DM, CKD, cancer ▪ Elderly	• Peripartum sepsis and neonatal infection • Primary bacteremia • Skin and soft tissue infection • Septic arthritis (mono-polyarthritis)
Streptococcus pneumoniae	▪ HIV ▪ Asplenia ▪ Humoral defects ▪ Elderly	• Pneumonia • Meningitis • Invasive pneumococcal disease (IPD)

 *Streptococcus & Enterococcus* spp.

Species	Susceptible hosts	Common clinical syndromes
Streptococcus suis	▪ Normal host ▪ (Exposure to pork)	▪ Meningitis ▪ Bacteremia
Streptococcus gallolyticus *Streptococcus pasterianus* (GDS)	▪ Elderly ▪ Chronic liver disease	▪ Bacteremia ▪ Infective endocarditis ▪ Hepatobiliary tract infections and IAI ▪ Associated with colonic cancer (*S. gallolyticus*)
Viridans streptococci	▪ Preexisting valve ▪ Neutropenia	▪ Bacteremia in neutropenic host ▪ Infective endocarditis ▪ Abscess (*S. anginosus* group)
Enteroccoccus	▪ Elderly ▪ Broad spectrum ATB	▪ Bacteremia ▪ Intraabdominal infection ▪ Urinary tract infection

Clostridioides difficile

Risks: ATB (esp. clindamycin, beta-lactam), PPI, older age, previous hospitalization, NG tube

Investigations: PCR for toxin genes, GDH Ag

Severity	Treatment
Initial episode	Fidaxomicin 200 mg PO q 12 h x 10 days Alt: Vancomycin 125 mg PO qid x 10 days
Fulminant	Vancomycin 500 mg NG feed qid + metronidazole 500 mg IV q 8 h x 10 days (consider vancomycin rectum if ileus)

Infection control: contact precaution for duration of illness

Use antiseptic but do not use alcohol hand rub (cannot kill spore)

Actinomyces spp.

Modified acid fast negative bacilli

- Orocervical: poor denture
- Thoracic: aspiration, esophageal perforation
- Abdominal: occult GI perforation, fish bone
- Pelvic: intrauterine device

Treatment

- Penicillin G, amoxicillin
- Resistant to metronidazole
- Duration: 3-6 months



Neisseria meningitidis

Syndrome: meningococcemia & acute meningitis

High risk: complement deficiency (esp. terminal complement), eculizumab

Infection control: droplet precaution 24 hours after antibiotic treatment

Indication for post-exposure prophylaxis

- Close contact environments (e.g. household, long term care)
- Exposure to oral secretion: kissing, mouth to mouth PCR
- High risk healthcare worker: intubation, suctioning

Antibiotic prophylaxis

- Ciprofloxacin 500 mg po single dose
- Rifampicin 600 mg po q 12 h x 4 doses
- Ceftriaxone 250 mg IM single dose

Klebsiella pneumoniae

Clinical syndrome

- Friedlander's disease: Upper lobar pneumonia in chronic alcoholic patients
- Hepatobiliary infection
- UTI
- CNS infection
- **Distinctive syndrome**
  - Hypermucoid strain of *K. pneumoniae* (K1/K2)
  - Common in Asian descent with diabetes
  - Liver abscess with extrahepatic Cx: CNS, endophthalmitis, septic pulmonary emboli and empyema



Proteus mirabilis

Community and nosocomial UTI

Risk factor: urinary catheter

Struvite stone

- Urease → urine alkalinisation
- Magnesium ammonium phosphate crystal



Treatment

- Ceftriaxone IV
- ESBL producing → carbapenem/piperacillin-tazobactam
- High MIC to imipenem
- Intrinsic resistant to nitrofurantoin, colistin

Burkholderia pseudomallei

Risk factors

Factors	OR
Thalassemia	11.8
DM and high soil/water exposure	6.3
Diabetes mellitus	4.8
High soil/water exposure	2.6
Pre-existing renal disease	2.6

Clinical manifestation

- Septicemia
- Acute & chronic pneumonia
- Hepatosplenic abscess (Cartwheel or Swiss cheese)
- Parotid & prostatic abscess, mycotic aneurysm

Investigation

- Culture, melioid titer (limited use in endemic area)

Treatment

- Ceftazidime 2 g IV q 8 h for 10-14 D
- Imipenem (RCT: ↓ treatment failure) or meropenem (Cohort: ↓sepsis related death)

Maintenance phase (12-20 weeks)

- Co-trimoxazole SS 4x2 po (>60 kg), 3x2 po (40-60 kg), 2x2 po (<40 kg)

Orientia & Rickettsia

CC: acute fever, headache & myalgia, MP rash

	Orientia tsusugamushi	*Rickettsia typhi*
Vector	Chigger 	Rat flea 
Disease	Scrub typhus	Murine typhus
Eschar	May be found (50-80%) 	No
Complications	Aseptic meningitis, encephalitis, pneumonitis, hepatitis	
Investigation	IFA, Weil-Felix test (non-specific and rarely used)	
Treatment	Doxycycline 100 mg po bid x 7 D or azithromycin 500 mg po OD x 3 D	

Leptospira interrogans

Anicteric leptospirosis

- Fever with myalgia esp. calf & back
- Conjunctival suffusion & hemorrhage
- May have aseptic meningitis

Investigation

- Gold standard: Microagglutination test
- Widely available test: IFA
- PCR

Weil's syndrome

- Jaundice
- Acute renal failure
- Myocarditis
- Pulmonary hemorrhage & ARDS

Treatment

- Mild form: doxycycline or azithromycin
- Severe form: PGS/ceftriaxone IV 7 D

Treponema pallidum

Primary syphilis

↓ 4-10 wk

Secondary syphilis

↓

Latent syphilis → Tertiary syphilis

untreated

Serology	Type	Characteristics	False +ve/-ve
❑ VDRL ❑ RPR	Non-treponemal	▪ Reflect disease activity	▪ False –ve: 1º, 3º, previous Rx, prozone ▪ False +ve: elderly, pregnacy, autoimmune
❑ TPHA ❑ FTA-ABS ❑ CMIA	Treponemal	▪ Persistent positive ▪ Higher specificity	▪ Less false +ve

Treponema pallidum

Stage	Recommended treatment	F/U (clinical + VDRL)
Primary Secondary Early latent (<1 Y)	Benzathine penicillin G 2.4 mU IM single dose	6, 12 M
Late latent (>1 Y) Unknown duration	Benzathine penicillin G 2.4 mU IM weekly x 3 weeks	6, 12, 24 M
Tertiary	Benzathine penicillin G 2.4 mU IM weekly x 3 weeks	Limited information
Neurosyphilis Ocular or otosyphilis	Aqueous crystalline penicillin G 18-24 mU/d x 10-14 days	Repeated CSF are unnecessary

- **HIV:** treated as non-HIV
- **Pregnancy:** penicillin only, if allergy → desensitized
- **Rx sex partner:** exposed within 90 D with early SY or exposed to latent SY with titer > 1:32

Nontuberculous mycobacteria

Cutaneous: fish tank granuloma (*M. marinum*), trauma or cosmetic related (RGM esp. *M. abscessus*)

Disseminated disease: LN + reactive skin in anti-IFN gamma autoAb (*M. abscessus,* MAC), HIV (MAC)

Pulmonary disease (Require 2 sputum C/S or 1 BAL C/S for diagnosis)

Fibrocavitary disease

Male smokers; usually early 50S

- Upper lobe cavitary
- MAC, *M. kansasii*

Nodular bronchiectasis

Female nonsmokers; usually > 60 year

- RML and lingular lobe nodular bronchiectasis
- MAC, *M. abscessus*

Hypersensitivity pneumonitis

Younger; usually non-smoker

- Diffuse reticulonodular infiltration, GGO
- MAC (hot tub), *M. immunogenum* (metal working)

Dengue virus

Dengue fever (DF)

- Fever with myalgia
- Headache and retro-orbital pain
- Hemorrhagic manifestation

Dengue hemorrhagic fever (DHF)

- Evidence of plasma leakage (↑Hct >20%, pleural effusion ascites, hypotension)





CBC: leukopenia (band), thrombocytopenia, ↑Hct

PBS: Atypical lymphocyte

1º infection: ↓ Sn of NS1 after D3 +ve Dengue IgM D5-14

2º infection: false -ve NS1 +ve Dengue IgG >> IgM

Treatment: supportive treatment

Prevention: DEET, dengue vaccine (Qdenga at 0, 3 M)

Arthropod borne virus

	Dengue	Chikungunya	Zika
Genus	*Flavivirus*	*Alphavirus*	*Flavivirus*
Fever	**+++**	++	+/-
Headache	**+++**	+	+
Myalgia	**+++**	++	+
Arthralgia	+/-	**+++**	+
Maculopapular rash	+	++	**+++**
Non-purulent conjunctivitis	-	++	**+++**
Thrombocytopenia	**+++**	+/-	+/-
Shock syndrome	**+++**	-	-
Neurological complications	Encephalitis	Encephalitis/ GBS	GBS, microcephaly

Varicella zoster disease

Diagnosis

- Tzanck smear: multinucleated giant cell
- VZV antigen, PCR

Treatment

- Acyclovir 800 mg po 5 times/day or 10 mg/kg IV q 8 h
- Varicella: all adult patients within 24 hours
- Zoster: ≥50 years within 72 hours, disseminated, IC hosts

PEP in nonvaccinated patients

- Immunocompetent: vaccination within 5 D
- Immunocompromised/pregnancy: VARIZIG within 10 D or acyclovir PO given at D7

Cytomegalovirus

Transmission: sexual, blood and HSCT/solid organ transplant

Common clinical syndromes

- Immunocompetent: mononucleosis-like syndrome (less tonsillitis/lymphadenopathy)
- Immunocompromised host: CMV syndrome and disease



Retinitis
Cheese & Ketchup appearance



Colitis
Diffuse mucosal hemorrhage with ulcer

Pneumonitis
Interstitial pneumonia

Encephalitis
Periventricular lesions



Treatment

- Ganciclovir IV
- Valganciclovir po

Influenza virus

Transmission: droplet & opportunistic airborne

Clinical manifestation

- Systemic symptoms → respiratory symptoms
- High grade fever with abrupt onset, headache, fatigue and myalgia
- Runny nose, nonproductive cough, sore throat

Investigation

- NP swab/wash for PCR has better sensitivity compared with rapid antigen test

Influenza virus

Antiviral treatment

Influenza like illness

Regardless of onset
- **Greatest benefit < 48 h after onset**
  ↓ readmission & 30-day mortality
- **Some benefit < 5 D after onset**

Mild
Outpatient

- ✓ ≥ 65 years old or < 2 years old
- ✓ Asthma and chronic lung disease
- ✓ Neurologic, blood disorders, edocrine disorders, heart disease, kidney disease, liver disease
- ✓ Obesity (BMI ≥ 40 kg/m^2) and pregnancy
- ✓ <19 Y on long-term ASA use
- ✓ IC hosts
- ✓ Resident of LTCF

Severe, complicated
Hospitalized patient

High risk
for complications

Antiviral treatment as soon as possible

Low risk
for complications

May be consider if onset < 48 hours

Only if < 48 hours after onset
↓ fever for 1 day

COVID-19

Transmission: droplet, airborne in appropriate environment

Incubation period: 2-14 days (average 4-5 days)

Clinical manifestations

- 80% asymptomatic or URI
- 20% pneumonia (high risk: > 60 y, obesity, comorbidities, IC host)

Investigation: NP swab for PCR

Treatment

- High risk: molnupiravir 5 D, nirmatrelvir/ritonavir 5 D, remdesivir 3 D
- Pneumonia: remdesivir 5-10 D, corticosteroid for desaturated patients

Prevention

- COVID-19 vaccine (Comirnaty®) booster for high-risk patients



Monkeypox virus

Mpox disease

IP: 5-21 days

Cutaneous manifestations

- Firm/rubbery, well-circumscribed, deep-seated ± umbilicated lesions
- Location: Genital & anorectal, oral areas ± palms & soles
- Painful lesions (initial) → itchy lesions (healing)

Other manifestations

- Prodromal symptoms (fever, chills, LN, myalgias, headache)
- Rectal symptoms (purulent/bloody stools, rectal pain/bleeding)

Investigation: PCR

Treatment: tecovirimat 14 D for IC host, pregnant woman, severe symptoms, necrotic/hemorrhagic lesion, sensitive area (eye, throat, prepuce, vagina, rectal)

Candida spp.

Risk factors

- Neutropenia
- Broad spectrum ATB
- Abdominal surgery/perforation
- TPN, HD, ICU admission

Clinical syndromes for invasive type

- Candidemia: mimic bacterial sepsis
- Acute disseminated candidiasis
- Chronic hepatosplenic candidiasis
- Deep organ candidiasis



Budding yeast with pseudohyphae

Empirical treatment

- Echinocandin (alternative: amphotericin B)
- Step down to fluconazole if susceptible



Dimorphic fungi

Talaromyces marneffei





Histoplasma capsulatum

Binary fission	Budding yeast
More skin lesions (umbilicated lesions)	More oral mucosal lesions May have adrenal gland involvement
Fungal C/S (rapid growth with red pigment)	Fungal C/S (prolonged incubation period), *Histoplasma* Ag
AMBd 0.7 mKD then itraconazole	

Sporothrix spp.

Sporotrichosis

Pathogenesis: direct skin inoculation

- Sapronotic transmission: contaminated plant material or soil
- Zoonotic transmission: domestic cat >> dog, reptile, rodents

Investigation

- KOH (low Sn), fungal C/S

Treatment

- Itraconazole 200-400 mg/day 3-6 M, +/- adjunctive cryosurgery

Fixed

Verrucous plaque with crust, satellite nodules

Sporotrichoid

Lymphatic spreading

Lymphadenopathy

Mucorales

- Rhino-orbito-cerebral mucormycosis in diabetic patients
- Pulmonary in SOT recipients, cutaneous infection after trauma



Diagnosis

- Histopathology: broad or pauci-septate hyphae (ribbon like appearance)
- Culture, PCR



Treatment

1. Reversal of immunosuppression
2. Adequate surgery
3. Antifungal therapy
   - AMBd 1-1.5 mg/kg/day or L-AMB 5-10 mg/kg/day
   - Alternative agents: isavuconazole & posaconazole

Gastrointestinal helminth

Intestinal obstruction



Ascaris lumbricoides

Iron deficiency anemia

Hookworm

Diarrhea
Rectal prolapse

Trichuris trichiura

Chronic diarrhea
Malabsorption

Capillaria phillippinensis

Taenia spp.



Cholangiocarcinoma

Opisthorchis viverrini

Strongyloides stercoralis

- Soil-transmitted helminth (infective stage - filariform larva)
- High risk: steroid user

Clinical manifestation

- GI: diarrhea, malabsorption syndrome
- Larva currens
- Hyperinfection (lung) & Disseminated infection (extra-intestinal/lung)
- Unexplained source of GNR sepsis

Filariform larva: notch tail

Rhabditiform larva: point tail

Investigation

- Sputum & stool fresh smear, antibody (EIA)

Treatment

- Ivermectin (200 mcg/kg x 2 days for GI, 14 D after –ve smear for severe disease)

Gastrointestinal protozoa



Cystoisospora belli
Rx: cotrimoxazole



Cyclospora cayetanensis
Rx: cotrimoxazole



***Cryptosporidium* spp.**
Rx: ART



Microsporidia
Rx: ART





***Giardia* spp.**
Rx: metronidazole

Plasmodium spp.

CC: fever with chills, anemia & jaundice, mild hepatosplenomegaly



P. falciparum
Normal size infected RBC
Thin RF, **multiple infection/double chromatin**
Gametocyte-banana shaped

P. vivax
Large infected RBC
Thick RF
Growing trophozoite- amoeboid form

Treatment

- Severe: IV Artesunate → non-severe regimen
- PF: dihydroartemisinin/piperaquine or artesunate/pyronaridine (resistant area) + SD primaquine
- Non-PF: chloroquine + primaquine (PV/PO)

Leishmania spp.



Common in southern region of Thailand

- Visceral leishmaniasis (prolonged fever, hepatosplenomegaly, pancytopenia)
- Cutanoeus, mucocutaneous leishmaniasis
- Species: *L. martiniquensis, L. siamensis*
- Rx: liposomal amphotericin B, miltefosine

Outline

- Organ specific infections
- Selected specific pathogens
- **HIV infection**

HIV infection

Viral component testing

- P24 antigen
- HIV RNA
- Viral culture

Antibody testing

- ELISA
- Particle agglutination assay
- Immunochromatography
- Western blot



Acute retroviral syndrome

- Fever, arthralgia, oral ulcer, rash, diarrhea
- HIV RNA
- May have inconclusive anti-HIV test

HIV infection

When to start ART

- No OI: Rapid (<7D) or same day ART
- With OI: Delay ART to prevent IRIS

TB	Any CD4	2-4 wk
	CNS TB	4-8 wk
Cryptococcal meningitis		4-6 wk
Non-CNS cryptoccosis		2-4 wk
Cerebral toxoplasmosis		2-4 wk
CMV infection		Defer to 2 wk
Other OIs		Within 2 wk

Before ART

- CD4 < 200: co-trimoxazole prophylaxis
- Screening OIs

HBV	All	HBsAg, anti-HBc
HCV		Anti-HCV
Syphilis		VDRL, TPHA
TB		CXR
CMV	CD4 < 100	Ophthalmoscopy
Cryptococcus		Serum crypto Ag

HIV infection

IAS-USA 2024	DHHS 2024	EACS 2024	Thai 2021/2022
Recommended Initial Regimens (ART-naïve Adults) 2 NRTIs + INSTI			
▪ TAF or TDF + FTC or 3TC + DTG ▪ TAF/FTC/BIC	▪ TAF or TDF + FTC or 3TC + DTG ▪ TAF/FTC/BIC	▪ TAF/FTC or TDF/XTC + DTG ▪ TAF/FTC/BIC	▪ TAF or TDF + FTC or 3TC + DTG

Alternative regimens

- ABC/3TC + DTG if could not tolerate TDF/TAF & negative HLA-B*57:01
- 3TC/DTG if HBs Ag –ve, HIV RNA < 500,000 copies/mL and no 3TC resistance
- 2 NRTIs + PI/r or PI/c if having history of long acting cabotegravir use as PrEP

HIV infection

Adverse drug reactions

NRTI

- **AZT:** bone marrow suppression. Lactic acidosis, myopathy
- **TDF:** nephropathy (↓GFR, Fanconi syndrome), osteopenia
- **TAF:** Weight gain
- **ABC:** hypersensitivity reaction (check HLAB*57:01), cardiovascular disease (IHD, CVA)

NNRTI

- **Nevirapine:** rash, severe hepatitis
- **Efavirenz:** dizziness, depression, rash, hyperlipidemia

PI

- **Lopinavir:** diarrhea, dyslipidemia
- **Atazanavir:** hyperbilirubinemia, renal stone

INSTI

- **DTG:** Weight gain, ↑serum Cr (impaired tubular excretion of Cr without GFR change), insomnia
- **BIC:** Weight gain (more than DTG), ↑serum Cr

HIV infection

ARV in special population

High cardiac risk	Avoid using ABC (↑ MI and stroke)
Cirrhosis	Avoid using ABC, AZT, NVP, EFV
Weight gain concern	Avoid using BIC, DTG, TAF
Psychiatric illness	Avoid using EFV, RPV
▪ Rifampicin use	Avoid using PI/r, PI/c, RPV, ETV, BIC ▪ DTG 50 mg bid ▪ EFV 600 mg OD
Ergot use	Avoid using PI/r, PI/c
Statin use	Avoid using PI/r, PI/c with simvastatin or lovastatin
Metformin use	Avoid using high dose MFM with DTG
Polyvalent cation use	Take DTG, BIC 2 h before or 6 h after supplement

Good luck